Status:

SUSPENDED

Evaluation of ReX-C® System for Medication Adherence in Oncology Patients Taking Oral Oncolytics

Lead Sponsor:

Dosentrx Ltd.

Conditions:

Oncology

Adherence, Medication

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

In recent decades, an increasing number of oral anticancer medications (oral oncolytics) have been approved. Oral oncolytics now make up to 30% of the oncology market, and their use is continually exp...

Detailed Description

ReX is a hand-held, mobile device intended to provide solid oral medication on patient demand according to a pre-programmed treatment protocol. ReX addresses poor patient adherence, tracks patient's r...

Eligibility Criteria

Inclusion

  • Male or Female, at least 18 years of age
  • Subject is able to swallow pills and during training successfully achieves 2 administrations of "demo" pills (Tic-Tac mints) by the ReX-C.
  • Subject is able to read and understand the Informed Consent Form.
  • Subject was diagnosed with cancer and receives oral oncology medication.
  • Subject is intended to receive Afinitor OR Sutent OR Lenvima during the 2 months study period.
  • Subject takes medication therapy at home.
  • Subject is fluent in one of the following languages: Hebrew, English, Russian, Arabic.

Exclusion

  • Subject has physical or mental disabilities which prevents their enrolment in this study, such as poor fine motor skills, impaired visual or auditory faculties, mental disorders or other impairment affecting ability to provide Informed Consent or use the ReX-C dispensing unit effectively.
  • Subject failed to extract 2 Tic-Tacs with the Rex-C device during training.
  • Subject is participating in another clinical study that does not permit participation in two studies simultaneously.
  • Subject is at end stage or terminal illness with anticipated life expectancy of less than 3 months.

Key Trial Info

Start Date :

April 21 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 1 2023

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT04091711

Start Date

April 21 2020

End Date

February 1 2023

Last Update

September 20 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Oncology Unit, Tel Aviv Sourasky Medical Center

Tel Aviv, Israel